---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Clinical trials questions"
description: "Clinical trials questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How was Ubrelvy studied in its pivotal acute migraine trials? How many patients were pain free 2 hours after Ubrelvy vs placebo? Does Ubrelvy relieve the most bothersome migraine symptom at 2 hours vs placebo? Does Ubrelvy relieve migraine pain at 2 hours vs placebo? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Study results

<a id="ubrelvy-pivotal-trial-design"></a>

### How was Ubrelvy studied in its pivotal acute migraine trials?

> “The efficacy of UBRELVY for the acute treatment of migraine was demonstrated in two 
> randomized, double-blind, placebo-controlled trials [Study 1 (NCT02828020) and Study 2”

Source: [UBRELVY: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=11)

> “(NCT02867709)]. Study 1 randomized patients to placebo (n=559) or UBRELVY 50 mg 
> (n=556) or 100 mg (n=557) and Study 2 randomized patients to placebo (n=563) or UBRELVY 
> 50 mg (n=562). In all studies, patients were instructed to treat a migraine with moderate to severe 
> headache pain intensity. A second dose of study medication (UBRELVY or placebo), or the 
> patient’s usual acute treatment for migraine, was allowed between 2 to 48 hours after the initial 
> treatment for a non-responding or recurrent migraine headache. Up to 23% of patients were 
> taking preventive medications for migraine at baseline. None of these patients were on 
> concomitant preventive medication that act on the CGRP pathway.”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “The primary efficacy analyses were conducted in patients who treated a migraine with moderate 
> to severe pain. The efficacy of UBRELVY was established by an effect on pain freedom at 2 
> hours post-dose and most bothersome symptom (MBS) freedom at 2 hours post-dose, compared 
> to placebo, for Studies 1 and 2. Pain freedom was defined as a reduction of moderate or severe 
> headache pain to no pain, and MBS freedom was defined as the absence of the self-identified 
> MBS (i.e., photophobia, phonophobia, or nausea). Among patients who selected an MBS, the 
> most commonly selected was photophobia (56%), followed by phonophobia (24%), and nausea 
> (19%).”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “*In pivotal clinical studies, patients took UBRELVY within 4 hours of migraine headache onset.<sup>6</sup>”

Source: [UBRELVY: Acute Migraine Treatment, captured 2026-11-14](https://www.ubrelvyhcp.com/#:~:text=%2AIn%20pivotal%20clinical%20studies%2C%20patients,4%20hours%20of%20migraine%20headache)

Note: The label calls the pivotal trials Study 1 and Study 2; the safety page of the Ubrelvy HCP site refers to them as ACHIEVE I and II. The last passage is from the home page of the Ubrelvy HCP site, which cites Dodick et al., Headache 2020.

<a id="ubrelvy-pain-free-2-hours"></a>

### How many patients were pain free 2 hours after Ubrelvy vs placebo?

> “Table 3: Migraine Efficacy Endpoints for Study 1 and Study 2 
>
> Study 1 
> Study 2 
>
> UBRELVY 
> 50 mg 
> UBRELVY 
> 100 mg 
> Placebo 
> UBRELVY 
> 50 mg 
> Placebo”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Pain Free at 2 hours 
> N 
> 422 
> 448 
> 456 
> 464 
> 456 
> % Responders 
> 19.2 
> 21.2 
> 11.8 
> 21.8 
> 14.3 
> Difference from placebo (%) 
> 7.4 
> 9.4 
>
> 7.5 
>
> p value 
> 0.002 
> <0.001 
>
> 0.007”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Co-primary endpoint:
> Pain freedom at 2 hours with a single dose<sup>1,2</sup>*
>
> 21<sup>%</sup>
> of patients
> UBRELVY® 100 mg (95/448) vs 12% placebo (54/456)<sup>1,2†</sup>
>
> <sup>†</sup>
> P<0.001.<sup>1</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=Co%2Dprimary%20endpoint%3A,mg%20%2895%2F448%29%20vs%2012%25%20placebo)

> “*Pain freedom was defined as a reduction from moderate or severe headache pain to no pain.<sup>1</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=%2APain%20freedom%20was%20defined%20as,severe%20headache%20pain%20to%20no)

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. The results page of the Ubrelvy HCP site reports the Study 1 result for UBRELVY 100 mg.

<a id="ubrelvy-most-bothersome-symptom"></a>

### Does Ubrelvy relieve the most bothersome migraine symptom at 2 hours vs placebo?

> “MBS freedom was defined as the absence of the self-identified 
> MBS (i.e., photophobia, phonophobia, or nausea). Among patients who selected an MBS, the 
> most commonly selected was photophobia (56%), followed by phonophobia (24%), and nausea 
> (19%).”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Table 3: Migraine Efficacy Endpoints for Study 1 and Study 2 
>
> Study 1 
> Study 2 
>
> UBRELVY 
> 50 mg 
> UBRELVY 
> 100 mg 
> Placebo 
> UBRELVY 
> 50 mg 
> Placebo”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Most Bothersome Symptom Free at 2 hours 
>
>
> N 
> 420 
> 448 
> 454 
> 463 
> 456 
> % Responders 
> 38.6 
> 37.7 
> 27.8 
> 38.9 
> 27.4 
> Difference from placebo (%) 
> 10.8 
> 9.9 
>
> 11.5 
>
> p value 
> <0.001 
> <0.001 
>
> <0.001”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “The incidence of photophobia and phonophobia was reduced following administration of 
> UBRELVY at both doses (50 mg and 100 mg) as compared to placebo.”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. Most bothersome symptom (MBS) freedom at 2 hours was a co-primary endpoint of both studies.

<a id="ubrelvy-pain-relief-2-hours"></a>

### Does Ubrelvy relieve migraine pain at 2 hours vs placebo?

> “Table 3 also presents the results of the analyses of the 
> percentage of patients achieving pain relief at 2 hours (defined as a reduction in migraine pain 
> from moderate or severe to mild or none) post-dose and the percentage of patients achieving 
> sustained pain freedom between 2 to 24 hours post-dose.”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Table 3: Migraine Efficacy Endpoints for Study 1 and Study 2 
>
> Study 1 
> Study 2 
>
> UBRELVY 
> 50 mg 
> UBRELVY 
> 100 mg 
> Placebo 
> UBRELVY 
> 50 mg 
> Placebo”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Pain Relief at 2 hours 
>
>
> N 
> 422 
> 448 
> 456 
> 464 
> 456 
> % Responders 
> 60.7 
> 61.4 
> 49.1 
> 62.7 
> 48.2 
> p value 
> <0.001 
> <0.001 
>
> <0.001”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain.

<a id="ubrelvy-sustained-pain-freedom"></a>

### How many patients stayed pain free 2 to 24 hours after Ubrelvy vs placebo?

> “Table 3: Migraine Efficacy Endpoints for Study 1 and Study 2 
>
> Study 1 
> Study 2 
>
> UBRELVY 
> 50 mg 
> UBRELVY 
> 100 mg 
> Placebo 
> UBRELVY 
> 50 mg 
> Placebo”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “Sustained Pain Freedom 2-24 hours”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

> “N 
> 418 
> 441 
> 452 
> 457 
> 451 
> % Responders 
> 12.7 
> 15.4 
> 8.6 
> 14.4 
> 8.2 
> p value 
> *NS 
> 0.002 
>
> 0.005 
>
> * Not statistically significant (NS)”

Source: [UBRELVY: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=13)

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. The table continues onto the next page of the label, which gives the sustained pain freedom values.

<a id="ubrelvy-prodrome"></a>

### Did patients taking Ubrelvy in the prodrome avoid moderate to severe headache vs placebo?

> “Primary endpoint:
> Absence of headache pain of moderate to severe intensity within 24 hours after taking UBRELVY 100 mg in the prodrome phase (defined in the study as 1-6 hours prior to onset of headache)<sup>3</sup>
>
> 46%<sup>‡</sup>	OF PATIENTS WHO TOOK UBRELVY 100 mg IN THE PRODROME PHASE (190/418) VS 29% PLACEBO (121/423) AVOIDED INTENSE HEAD PAIN BEFORE IT STARTED THROUGH 24 HOURS<sup>3</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=Absence%20of%20headache%20pain%20of,BEFORE%20IT%20STARTED%20THROUGH%2024)

> “<sup>‡</sup>P<0.0001 vs placebo.<sup>3</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=%E2%80%A1P%3C0.0001%20vs%20placebo.3)

> “Odds ratio 2.09 (95% CI, 1.63-2.69)<sup>3||</sup>
> mITT=477 participants.<sup>3¶</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=Odds%20ratio%202.09%20%2895%25%20CI%2C,mITT%3D477)

> “LIMITATIONS: This study evaluated a subset of the migraine population who could reliably predict the onset of migraine headache pain (per clinician judgment) within a short time window. Patients should be carefully assessed on their ability to accurately predict the onset of a migraine attack and progression to the headache phase. The 50 mg dose was not assessed. Patients were not allowed to administer a second dose.”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=LIMITATIONS%3A%20This%20study%20evaluated%20a,to%20administer%20a%20second%20dose.)

> “Study Design<sup>3</sup>: A phase 3, multicenter, randomized, double-blind, placebo-controlled, crossover study that evaluated the absence of headache pain of moderate to severe intensity within 24 hours postdose after taking a single dose of UBRELVY 100 mg during the prodrome phase.”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=a%20second%20dose.-,Study,mg%20during%20the%20prodrome%20phase.)

> “No conclusions can be made about the efficacy of UBRELVY for prodrome symptoms.”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=No%20conclusions%20can%20be%20made,of%20UBRELVY%20for%20prodrome%20symptoms.)

> “Odds ratio (95% CI) was based on a generalized linear mixed model with treatment group and treatment period as categorical fixed effects.<sup>3</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=Odds%20ratio%20%2895%25%20CI%29%20was,treatment%20period%20as%20categorical%20fixed)

> “The mITT population consisted of all randomized participants with at least 1 assessment of headache occurrence within 24 hours after taking double-blind study intervention for at least 1 qualifying prodrome event during the double-blind treatment period.<sup>3</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=The%20mITT%20population%20consisted%20of,event%20during%20the%20double%2Dblind%20treatment)

Note: The prodrome study is described on the results page of the Ubrelvy HCP site, which cites Dodick et al., Lancet 2023. The Ubrelvy Prescribing Information does not describe this study.

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
